行业分析 |
|
|
|
|
抗体偶联药物国内研发现状及企业布局分析 |
陈文洁(),苗先锋 |
杭州费尔斯通科技有限公司 杭州 310051 |
|
Domestic Research and Development Status of Antibody-drug Conjugates and Strategic Layout of Key Enterprises |
CHEN Wen-jie(),MIAO Xian-feng |
Hangzhou Firestone Technology Co. Ltd., Hangzhou 310051, China |
[1] |
Khongorzul P, Ling C J, Khan F U, et al. Antibody-drug conjugates: a comprehensive review. Molecular Cancer Research, 2020, 18(1):3-19.
doi: 10.1158/1541-7786.MCR-19-0582
|
[2] |
Perez H L, Cardarelli P M, Deshpande S, et al. Antibody-drug conjugates: current status and future directions. Drug Discovery Today, 2014, 19(7):869-881.
doi: 10.1016/j.drudis.2013.11.004
|
[3] |
Antibody drug conjugates market size, share & trends analysis report by application (brain tumor, blood, breast, ovarian, lung cancer), by technology (cleavable, non-cleavable linker), and segment forecasts, 2019-2025. [2019-01-30]. https://www.grandviewresearch.com/industry-analysis/antibody-drug-conjugates-market.
|
[4] |
Tsuchikama K, An Z Q. Antibody-drug conjugates: recent advancesin conjugation and linker chemistries. Protein&Cell, 2018, 9(1):33-46.
|
[5] |
Pysz I, Jackson P J M, Thurston D E. Introduction to antibody-drug conjugates (ADCs) // Thurston D E, Jackson P J M. Cytotoxic payloads for antibody-drug conjugates. London: Royal Society of Chemistry, 2019:1-30.
|
|
Viewed |
|
|
|
Full text
|
|
|
|
|
Abstract
|
|
|
|
|
Cited |
|
|
|
|
|
Shared |
|
|
|
|
|
Discussed |
|
|
|
|